Cargando…
A Case of Pathological Complete Response and Resolution of Dermatomyositis Following Neoadjuvant Chemotherapy in HER2-Positive Early Breast Cancer
Introduction. Dermatomyositis (DM) is an idiopathic inflammatory myopathy (IIM) mainly characterized by subacute muscle weakness and skin rash sometimes associated with malignancy. Case Presentation. A 61-year-old female was admitted to our hospital because of progressive proximal muscular weakness,...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8161769/ https://www.ncbi.nlm.nih.gov/pubmed/34073827 http://dx.doi.org/10.3390/curroncol28030182 |
_version_ | 1783700571713175552 |
---|---|
author | Piras, Marta Panebianco, Martina Garibaldi, Matteo Roberto, Michela Merlonghi, Gioia Pellegrini, Patrizia Marchetti, Paolo |
author_facet | Piras, Marta Panebianco, Martina Garibaldi, Matteo Roberto, Michela Merlonghi, Gioia Pellegrini, Patrizia Marchetti, Paolo |
author_sort | Piras, Marta |
collection | PubMed |
description | Introduction. Dermatomyositis (DM) is an idiopathic inflammatory myopathy (IIM) mainly characterized by subacute muscle weakness and skin rash sometimes associated with malignancy. Case Presentation. A 61-year-old female was admitted to our hospital because of progressive proximal muscular weakness, heliotropic rash and left breast rash. Muscle biopsy findings were consistent with dermatomyositis (DM). A full panel of myositis associated (MAA) and specific antibodies (MSA) revealed the presence of anti-nuclear antibodies (1:160, speckled), Anti-Ro52 and anti TIF1-γ antibodies. A whole body Computed Tomography Scan showed three left mammary nodules and homolateral axillary lymphadenopathy. The breast biopsy confirmed the diagnosis of ductal carcinoma. Patient was initiated to neoadjuvant chemotherapy followed by surgery for cancer, and corticosteroid and intravenous immunoglobulins for DM with a complete resolution of muscle weakness and pathological complete response of breast cancer. Discussion and conclusion. Similar cases in literature are commonly referred to a first-line surgery and the role of neoadjuvant chemotherapy is debatable. |
format | Online Article Text |
id | pubmed-8161769 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-81617692021-05-29 A Case of Pathological Complete Response and Resolution of Dermatomyositis Following Neoadjuvant Chemotherapy in HER2-Positive Early Breast Cancer Piras, Marta Panebianco, Martina Garibaldi, Matteo Roberto, Michela Merlonghi, Gioia Pellegrini, Patrizia Marchetti, Paolo Curr Oncol Case Report Introduction. Dermatomyositis (DM) is an idiopathic inflammatory myopathy (IIM) mainly characterized by subacute muscle weakness and skin rash sometimes associated with malignancy. Case Presentation. A 61-year-old female was admitted to our hospital because of progressive proximal muscular weakness, heliotropic rash and left breast rash. Muscle biopsy findings were consistent with dermatomyositis (DM). A full panel of myositis associated (MAA) and specific antibodies (MSA) revealed the presence of anti-nuclear antibodies (1:160, speckled), Anti-Ro52 and anti TIF1-γ antibodies. A whole body Computed Tomography Scan showed three left mammary nodules and homolateral axillary lymphadenopathy. The breast biopsy confirmed the diagnosis of ductal carcinoma. Patient was initiated to neoadjuvant chemotherapy followed by surgery for cancer, and corticosteroid and intravenous immunoglobulins for DM with a complete resolution of muscle weakness and pathological complete response of breast cancer. Discussion and conclusion. Similar cases in literature are commonly referred to a first-line surgery and the role of neoadjuvant chemotherapy is debatable. MDPI 2021-05-24 /pmc/articles/PMC8161769/ /pubmed/34073827 http://dx.doi.org/10.3390/curroncol28030182 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Case Report Piras, Marta Panebianco, Martina Garibaldi, Matteo Roberto, Michela Merlonghi, Gioia Pellegrini, Patrizia Marchetti, Paolo A Case of Pathological Complete Response and Resolution of Dermatomyositis Following Neoadjuvant Chemotherapy in HER2-Positive Early Breast Cancer |
title | A Case of Pathological Complete Response and Resolution of Dermatomyositis Following Neoadjuvant Chemotherapy in HER2-Positive Early Breast Cancer |
title_full | A Case of Pathological Complete Response and Resolution of Dermatomyositis Following Neoadjuvant Chemotherapy in HER2-Positive Early Breast Cancer |
title_fullStr | A Case of Pathological Complete Response and Resolution of Dermatomyositis Following Neoadjuvant Chemotherapy in HER2-Positive Early Breast Cancer |
title_full_unstemmed | A Case of Pathological Complete Response and Resolution of Dermatomyositis Following Neoadjuvant Chemotherapy in HER2-Positive Early Breast Cancer |
title_short | A Case of Pathological Complete Response and Resolution of Dermatomyositis Following Neoadjuvant Chemotherapy in HER2-Positive Early Breast Cancer |
title_sort | case of pathological complete response and resolution of dermatomyositis following neoadjuvant chemotherapy in her2-positive early breast cancer |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8161769/ https://www.ncbi.nlm.nih.gov/pubmed/34073827 http://dx.doi.org/10.3390/curroncol28030182 |
work_keys_str_mv | AT pirasmarta acaseofpathologicalcompleteresponseandresolutionofdermatomyositisfollowingneoadjuvantchemotherapyinher2positiveearlybreastcancer AT panebiancomartina acaseofpathologicalcompleteresponseandresolutionofdermatomyositisfollowingneoadjuvantchemotherapyinher2positiveearlybreastcancer AT garibaldimatteo acaseofpathologicalcompleteresponseandresolutionofdermatomyositisfollowingneoadjuvantchemotherapyinher2positiveearlybreastcancer AT robertomichela acaseofpathologicalcompleteresponseandresolutionofdermatomyositisfollowingneoadjuvantchemotherapyinher2positiveearlybreastcancer AT merlonghigioia acaseofpathologicalcompleteresponseandresolutionofdermatomyositisfollowingneoadjuvantchemotherapyinher2positiveearlybreastcancer AT pellegrinipatrizia acaseofpathologicalcompleteresponseandresolutionofdermatomyositisfollowingneoadjuvantchemotherapyinher2positiveearlybreastcancer AT marchettipaolo acaseofpathologicalcompleteresponseandresolutionofdermatomyositisfollowingneoadjuvantchemotherapyinher2positiveearlybreastcancer AT pirasmarta caseofpathologicalcompleteresponseandresolutionofdermatomyositisfollowingneoadjuvantchemotherapyinher2positiveearlybreastcancer AT panebiancomartina caseofpathologicalcompleteresponseandresolutionofdermatomyositisfollowingneoadjuvantchemotherapyinher2positiveearlybreastcancer AT garibaldimatteo caseofpathologicalcompleteresponseandresolutionofdermatomyositisfollowingneoadjuvantchemotherapyinher2positiveearlybreastcancer AT robertomichela caseofpathologicalcompleteresponseandresolutionofdermatomyositisfollowingneoadjuvantchemotherapyinher2positiveearlybreastcancer AT merlonghigioia caseofpathologicalcompleteresponseandresolutionofdermatomyositisfollowingneoadjuvantchemotherapyinher2positiveearlybreastcancer AT pellegrinipatrizia caseofpathologicalcompleteresponseandresolutionofdermatomyositisfollowingneoadjuvantchemotherapyinher2positiveearlybreastcancer AT marchettipaolo caseofpathologicalcompleteresponseandresolutionofdermatomyositisfollowingneoadjuvantchemotherapyinher2positiveearlybreastcancer |